Overview

• The Flair trial enrolled 786 patients with untreated chronic lymphocytic leukaemia across 96 UK cancer centres
• Participants receiving ibrutinib plus venetoclax achieved a 94% progression-free survival rate at five years
• Two-year bone marrow assessments found 66% of patients on the combination therapy had undetectable cancer cells
• Patients on the dual targeted drugs reported fewer treatment-related side effects than those on chemotherapy or ibrutinib alone
• Led by Dr Talha Munir and funded by Cancer Research UK, AbbVie and Johnson & Johnson, the study underscores a shift toward personalised medicine in leukaemia care